|
|
|
Single-Agent IMC-C225 (ErbituxTM) Has Activity in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses the Epidermal Growth Factor Receptor (EGFr)
|
|
Leonard Saltz, MD
Memorial Sloan-Kettering Cancer Center
New York, NY, USA
|
|
|
|
Dr. Saltz previously showed that IMC-C225
(cetuximab, Erbitux) in combination with irinotecan is effective
for irinotecan-refractory, endothelial growth factor receptor
(EGFr)-positive colorectal cancer. This new report shows that
this monoclonal antibody also has modest activity as a single
agent. The most significant toxicities are allergic reactions
and an acne-like rash. Toxicities that patients experience on
cytotoxic chemotherapy were virtually nonexistent.
|
|
Copyright 
2000-2013 by HESCO International, Ltd. All rights reserved.
|
|
|
